Trials
4 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- IC-MPGN (2 trials), Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), Geographic Atrophy Secondary to Age-related Macular Degeneration, IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN) and 1 more
- Main trialPhase 2
- “This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).”In the company’s words, NCT07522099 on ClinicalTrials.gov
- Other names
- siRNA
Other drugs for IC-MPGN
- IptacopanNovartis · Phase 3
- FinerenoneBayer · Phase 3
- AtrasentanNovartis · Phase 3
- ZigakibartNovartis · Phase 3
- BHV-1400Biohaven · Phase 3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
Coming up4
- 31 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 10 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- 28 Feb 2030Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovCompletion date moved: 2028-12-31 to 2030-04-30 · ClinicalTrials.gov NCT06989359
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 10 Jul 2028 | Chinese Adults With Kidney Disease | |
| Phase 2Recruiting | 28 Feb 2030 | Phase 2 Study of ADX-038 in Participants With Geographic Atrophy | |
| Phase 2Recruiting | 30 Apr 2030 | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | |
| Phase 1/2Recruiting | 31 Mar 2028 | Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026